Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma-Reference-Cited by-同舟云学术

Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma

Published:2022-12-07 Issue:1 Volume:27 Page:1272-1281
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Deng Jili¹,Mi Lan¹,Wang Xiaopei²,Zhu Jun¹,Zhang Chen¹^ORCID,Song Yuqin¹

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China

2. Department of Lymphoma, Peking University International Hospital, Beijing, People’s Republic of China.

Funder

National Nature Science Foundation of China

Beijing Natural Science Foundation

Capital's Funds for Health Improvement and Research

Beijing Municipal Science & Technology Commission

Beijing Municipal Administration of Hospitals' Ascent Plan

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2150389

Reference29 articles.

1. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options

2. Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival

3. Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study

4. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary breast lymphoma: A rare case report;International Journal of Surgery Case Reports;2024-09

2. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy;Journal of the Formosan Medical Association;2024-01

3. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia;Hematology;2023-07-05

4. Clinicopathological characteristics, local treatment, and prognostic factors in IE/IIE primary breast lymphoma: a retrospective study of 67 patients;World Journal of Surgical Oncology;2023-04-10

5. Primary Breast Anaplastic Large-Cell Lymphoma;Journal of Cancer Research and Practice;2023